BiomX Ltd announced that it has received $32 million in its Series B equity round of funding led by existing investors OrbiMed Advisors, L.L.C., Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., Eight Partners, Health for Life Capital, fund managed by Seventure Partners, SBI JI Innovation Advisory Ltd., and new investor RMGP Biopharma Fund, fund managed by RMGP Biopharma Fund on February 20, 2019. The transaction also included participation from new European investors including Chong Kun Dang Pharmaceutical Corp. (KOSE:A185750), Handok Inc. (KOSE:A002390), KB Investment Co., Ltd. MiraeAsset, and Vincos Limited.

As a part of transaction, Yaron Breski of RM Global Partners LLC, Investment Arm, and Eric de la Fortelle, of Seventure Partners will join company's board of directors.